Our business concept
Swedish Orphan International offers products and services that meet medical needs in cases where existing treatments do not exist or are inadequate. We aim to provide patients, healthcare staff and the pharmaceutical industry with an international network specialising in the development, marketing and distribution of orphan drugs..

Vision
Swedish Orphan International shall continuously secure its position as the leading Orphan drug company by being:

• The Preferred partner and employer
• Profitable, dynamic, creative and development oriented

All in a value creating culture focusing on the customer and collaborator, where innovation, high and excellent quality service, high performance and high productivity go hand-in-hand with job satisfaction.

Background
Like orphan children, the development of orphan drugs requires special care and attention. The term was used for the first time in the US in the early 1980s, when patient organisations for rare diseases made politicians aware of the fact that the pharmaceutical companies were reluctant to invest in developing products for the treatment of rare diseases since the relatively small market potential would make it impossible to meet the demands for return of investment and thereby would not justify the necessary investments.
 
Priorities for the future
In the future, our goal is to be even more active in the later stages of clinical development. By increasing our capability and competence in these phases and continuing to strengthen our expertise in regulatory issues, we will optimise the prospects for orphan drugs to reach the market.